Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior’s microRNA-targeting therapies aim to improve heart function, aligning with Novo’s focus on diabetes and obesity history.
Copyright © 2024 | WordPress Theme by MH Themes